Iovance Biotherapeutics Q3 revenue up 13%, backs FY outlook

Iovance Biotherapeutics

06/11/2025 13:12

Overview

Iovance Biotherapeutics Q3 rev grows 13% to ~$68 mln, gross margin improves to 43%

Adjusted loss per share for Q3 beats analyst expectations

Company expects cash position to fund operations into Q2 2027

Outlook

Iovance reaffirms 2025 revenue guidance of $250 to $300 mln

Centralizing manufacturing in early 2026 to improve margins

Potential Amtagvi approvals in UK and Australia expected in 2026

Result Drivers

AMTAGVI DEMAND - Increasing demand for Amtagvi as community treatment centers expand and drive earlier treatment

MARGIN IMPROVEMENT - Gross margin increased to 43% due to improved execution and cost optimization

GLOBAL EXPANSION - Recent approval in Canada and potential approvals in other countries to drive global growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$68 mln
Q3 EPS
Beat
-$0.25
-$0.26 (11 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Iovance Biotherapeutics Inc is $7.00, about 74.1% above its November 5 closing price of $1.81

Press Release: ID:nGNX24JwDQ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)